

Healthy Volunteers

## A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT02711423 2015-005132-17  
BP30042

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This two-part study is designed to assess the safety, tolerability, and PK of gantenerumab in healthy volunteers. Part I (dose escalation) will randomly assign participants to receive a single blinded SC dose of gantenerumab or placebo. Part II (PK extension) will randomly assign participants to receive a single open-label SC dose of ganenerumab at different dose levels according to safety assessments from Part I.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

**NCT02711423 2015-005132-17 BP30042**  
Trial Identifiers

### ***Eligibility Criteria:***

**Gender**  
Male

**Age**  
≥ 18 Years & ≤ 45 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers